DNDi is very pleased to announce the appointment of Dr Silvia Gold and Dr Kristine Husøy Onarheim as members of the organization’s Board of Directors.
Dr Silvia Gold holds a PhD in Biochemistry from the University of Buenos Aires. She is President of the Mundo Sano Foundation whose mission it is to improve the lives of people affected by neglected diseases.
Dr Gold is a member of the National Academy of Pharmacy and Biochemistry of Argentina and leads the Consortium for Research, Development, and Innovation on oncology therapies. Together with Hugo Sigman, she founded Grupo Insud and Insud Pharma, a multinational pharmaceutical company. She has contributed to numerous scientific publications and has actively participated in international meetings and conferences related to neglected tropical diseases and global public health.
Silvia Gold is a member of several boards, including the World Health Organization (WHO) Foundation Board; Petrie‐Flom Center for Health Law Policy, Harvard Law School; Center for International Development, Harvard Kennedy School; Uniting to Combat Executive Board; Advisory Council of the Barcelona Institute for Global Health; Board of Trustees of the Reina Sofia Foundation in Spain; and Economic and Social Council of Universidad Torcuato di Tella.
In 2019, Silvia Gold was awarded the Gold Medal from the Royal Academy of Medicine and Surgery of Murcia, Spain.
‘Throughout my career, it has been my mission to help people with neglected diseases by bringing people together and building strong partnerships. I am pleased to continue this mission by joining the Board of DNDi.’
Dr Silvia Gold
Dr Kristine Husøy Onarheim is a medical doctor and global health researcher. Dr Onarheim’s research focus on priority setting, policy making, and governance in global health, including work on access to medicines, university health coverage, migration health, women’s health, and children’s health.
Dr Onharheim is an affiliated researcher at the Bergen Centre for Ethics and Priority Setting, University of Bergen, Norway. She has been a research fellow at the Institute of Global Health, University College London and visiting researcher at Harvard T.H. Chan School of Public Health, Harvard University. As a medical doctor, she has clinical experience from Norway, Ethiopia, and India.
Dr Onarheim was a founding member of Universities Allied for Essential Medicines Norway and served on the board of Universities Allied for Essential Medicines Europe. She also was a founding member of the Lancet Youth Commission on Essential Medicines Policies.
‘Health innovation should be needs driven. We cannot continue to exclude and neglect diseases and populations. DNDi is a unique organization that provides an alternative model for drug research and development. Unequal access to medicines is an avoidable problem and I am proud to join DNDi to change status quo.’
Dr Kristine Husøy Onarheim
